BOLT - Long Setup Looking for a break above 14.03, Target 17.43, Target 2 $24.93. , Stop signal 11.87.
0%
0%
0%
0%
0%
−2.04USD
−88.098MUSD
5.729MUSD
23.582M
About Bolt Biotherapeutics, Inc.
Sector
CEO
Randall C. Schatzman
Headquarters
Redwood City
Website
Employees
94
Founded
2015
ISIN
US0977021049
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BOLT is featured.
